[20] Bendotti, Giulia, et al. "The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists." Pharmacological Research 182 (2022): 106320.[21] Nevola, Riccardo, et al. "GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives." ...
[12] Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., Fedele, E. 2018. Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus. Biofactors 44:148-157...
Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19:336-347. ...
[12] Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., Fedele, E. 2018. Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus. Biofactors 44:148-157. [13] Kandel, E.R. 2001. The molecular biology of me...
GLP-1类似物外周给药可通过抑制摄食量来降低体重[1-4,19]。根据分子构象(天然GLP-1或长效GLP-1类似物)和给药途径的不同,GLP-1及其类似物会通过不同的信号通路直接或间接地向中枢神经系统(CNS)传递减少摄食的信号。 在啮齿类动物,外周给予GLP-1R激动剂须通过中枢GLP-1R才能发挥食欲抑制效应[20,21],因为在中枢...
[7] Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A system...
[7] Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obe...
3 Choe, H. J. & Cho, Y. M. Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists.Endocrinol Metab(Seoul) 36, 22-29, doi:10.3803/EnM.2021.102 (2021). 4 Chen, D. et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mi...
GLP-1受体激动剂:超越其胰腺作用 完整文献全文翻译地址 Abstract 摘要 Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection ...
目前,胰高血糖素样肽1受体激动剂(glucagon-like peptide 1 receptor agonists,GLP-1RAs)是唯一一类已显示出有效治疗潜力的获批药物【1】。肽类激素葡萄糖依赖性促胰岛素肽(glucose-dependent insulinotropic peptide,GIP)和胰高血糖素(glucagon,GCG)在葡萄糖依赖性胰岛素分泌、食欲抑制、能量消耗和肝脏脂肪氧化等方面的...